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on the QT Interval
To the Editor:
I read with interest the paper "Influence of Heart Rate and Inhibition of Autonomic Tone on the QT Interval" by Ahnve and Vallin. I Their study confirms observations previously made in man in our laboratory.' Ahnve and Vallin also questioned in their discussion that "both heart rate and adrenergic activity affect the duration of the QT interval, but it is not clear as to what extent these effects are interrelated or whether the heart rate effects are independent of autonomic tone. We demonstrated in intact unanesthesized man and in one patient after cardiac transplantation that intravenous infusion of isoproterenol did not modify the duration of the QT interval independent of its effects on heart rate.3 In the patient with the cardiac transplant, the QT interval was markedly shortened at any given heart rate; however, we did not know whether that could be a normal finding in the denervated human heart.
ARMANDO SUSMANO, M.D. Rush Medical College Chicago, Illinois
Nifedipine in Hypertrophic Cardiomyopathy
We read with interest the excellent article, "Modification of Abnormal Left Ventricular Diastolic Properties by Nifedipine in Patients with Hypertrophic Cardiomyopathy" by Lorell et al. i After their preliminary reports on this subject, we confirmed their findings using ventriculography before and after nifedipine in five patients with hypertrophic cardiomyopathy. Our data also showed that left ventricular distensibility apparently increases after sublingual nifedipine in patients with hypertrophic cardiomyopathy. However, we seriously question the speculation that this improvement represents a specific myocardial effect of nifedipine. Indeed, in other patients with hypertrophic cardiomyopathy, we could induce similar changes in ventricular distensibility and relaxation after sublingual administration of nitroglycerin (I mg), while neither nitroglycerin nor nifedipine given by intracoronary injection improved left ventricular relaxation in this setting.2 3 These data suggest that a factor triggered only after systemic administration of nifedipine or nitroglycerin, rather than an effect on coronary vessels or on the myocardium, might be responsible for the observed effects. This factor could simply be the afterload reduction or a reflex increase in sympathetic stimulation. This hypothesis is further support- The authors repl/: To the Editor:
We appreciate the thoughtful comments of Drs. Pouleur and Rousseau and the kind acknowledgment that they have observed an improvement in diastolic properties after administration of sublingual nifedipine in patients with hypertrophic cardiomyopathy similar to that which we have reported. We agree that the mechanism of action is an important but unresolved issue that may include a direct myocardial effect, alteration of coronary blood flow and modification of left-heart loading conditions. To address the hypothesis that the effects of nifedipine on diastolic properties in hypertrophic cardiomyopathy are entirely due to the drug's vasodilator properties, we compared the effects of i.v. nitroprusside and sublingual nifedipine in 13 patients with hypertrophic cardiomyopathy.2 Despite a comparable reduction in left-heart loading conditions, assessed as peak left ventricular systolic pressure. nifedipine was associated with significantly greater improvement in left ventricular isovolumic relaxation and diastolic filling than nitroprusside.
This suggests that the effects of nifedipine cannot be entirely attributed to systemic vasodilation. The possibility of abnormal coronary vascular reserve, particularly involving the subendocardium, in hypertrophic cardiomyopathy and its modification by calcium-channel blockers needs further study. The study cited by Pouleur and Rousseau re2garding intracoronary application of nifedipine did not suggest a change in coronary blood flow, although the number of patients studied was small and a single dose was evaluated. 3 Other data suggest that nifedipine may promote an increase in coronary blood flow in patients with hypertrophic cardiomyopathy. Daly and co-workers4 recently reported that administration of sublingual nifedipine to patients with hypertrophic cardiomyopathy resulted in improved diastolic function at rest and during pacing tachycardia accompanied by an increase in coronary blood flow and reversal of myocardial lactate production. Third. the hypothesis that nifedipine's effects on diastolic mechanics may be related to reflex increases in sympathetic stimulation is an attractive hypothesis because the acute administration of verapamil5 and nifedipinel usually elicits a reduction of systemic blood pressure accompanied by a presumably reflex increase in heart rate. However, improvement in diastolic relaxation and filling has been observed in patients who showed no acute reflex increase in heart rate after nifedipinel and verapamil.6 Furthermore, the reflex increase in heart rate usually disappears after several days of calcium-channel blocker administration, and improvement in the depressed rate of diastolic filling has been observed after 36 hours of verapamil when no increase in heart rate relative to control was present.7
In summary. several groups have reported an improvement in abnormal diastolic mechanisms after nifedipine and verapamil. We suggest that further studies using a range of doses and comparing the effects of systemic and intracoronary administration of calcium-channel blockers
